Prior studies have demonstrated increased activation of p52 in breast, lung, prostate, pancreatic, and ovarian cancers [26–32], and increased expression has been linked to worse prognosis in lung cancer [33]. The gene discussed is NFKB2; the disease is ovarian carcinoma.